Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUCET vs PENTOTHAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.
Management of mild to moderate pain,Reduction of fever
Induction of general anesthesia,Induction of coma for increased intracranial pressure,Status epilepticus (off-label)
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.
2-4 hours (terminal); prolonged in renal impairment
Terminal elimination half-life is 5-12 hours (mean 8 hours) in adults. Prolonged with hepatic impairment, obesity, or high doses due to saturation of redistribution and metabolism.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Hepatic; primarily via CYP2C9 and other CYP450 enzymes.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Hepatic metabolism (approx. 80%), renal excretion of metabolites (20-30%) and unchanged drug (0.3-1%). Biliary/fecal elimination is negligible.
~85% bound to albumin
Approximately 72-86% bound, primarily to albumin (with some binding to lipoproteins).
0.3-0.5 L/kg; distributes primarily into extracellular fluid
Vd = 1.0-2.5 L/kg (mean 1.5 L/kg). High Vd due to extensive tissue distribution, including brain and fat; correlates with high lipid solubility.
Oral: 75-90%
IV: 100%. Rectal: approximately 60-80% (with variability). IM: approximately 60-70%. Oral: negligible due to extensive first-pass metabolism (not used clinically).
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
No specific GFR-based adjustment; use with caution in severe renal impairment due to prolonged effects.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Reduce dose by 50% in Child-Pugh B and C; monitor for prolonged sedation.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
Induction: 5-6 mg/kg IV; Maintenance: 1-2 mg/kg IV as needed; Rectal: 25 mg/kg (max 1.5 g).
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Reduce induction dose to 2-3 mg/kg IV; use lower maintenance doses; increased risk of hypotension and respiratory depression.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
WARNING: RESPIRATORY DEPRESSION AND APNEA; RESUSCITATIVE EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE. INTRA-ARTERIAL INJECTION MAY CAUSE ARTERIAL SPASM, THROMBOSIS, AND GANGRENE.
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Respiratory depression, hypotension, laryngospasm, bronchospasm, cardiac arrhythmias, extravasation risk, and acute porphyria exacerbation.
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Hypersensitivity to barbiturates, acute porphyria, severe respiratory or cardiovascular instability, and inadequate airway management capability.
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
No specific food interactions. However, avoid alcohol for at least 24 hours due to additive CNS depression.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk. Third trimester: prolonged maternal administration may cause neonatal respiratory depression, hypotonia, and withdrawal. Use only if clearly needed.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Thiopental is excreted in breast milk. M/P ratio is approximately 0.4–0.8. Infant dose is low (<1% of maternal weight-adjusted dose), but caution is advised due to potential CNS depression. American Academy of Pediatrics considers compatible with breastfeeding, but monitor infant for sedation.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
Pregnancy may increase volume of distribution and clearance, but dosing adjustments for thiopental are not routinely recommended. Use lowest effective dose due to increased sensitivity to barbiturates. For cesarean section, standard induction doses (3-5 mg/kg IV) are used; reduced doses may be needed if combined with other sedatives.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
Pentothal (thiopental) is an ultra-short-acting barbiturate used for induction of anesthesia. It causes dose-dependent respiratory depression and hypotension. Administer only in a controlled setting with resuscitation equipment. Note that it is highly alkaline (p H 10-11) and extravasation causes severe tissue necrosis. Also, it is contraindicated in porphyria.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
You will receive this medication only under the supervision of an anesthesiologist.,It will cause you to fall asleep quickly and you may feel drowsy for several hours after the procedure.,Do not drive or operate machinery for at least 24 hours after receiving this medication.,Inform your doctor if you have a history of porphyria, liver disease, or allergies to barbiturates.,You may experience a bad taste or cough upon injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUCET vs PENTOTHAL, answered by our medical review team.
BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. PENTOTHAL is a Barbiturate Anesthetic that works by Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUCET and PENTOTHAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. The standard adult dose of PENTOTHAL is: Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUCET and PENTOTHAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. PENTOTHAL is classified as Category C. PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.